Reliable genotypic tropism tests for the major HIV-1 subtypes

Kieran Cashin, Lachlan R. Gray, Katherine L. Harvey, Danielle Perez-Bercoff, Guinevere Q. Lee, Jasminka Sterjovski, Michael Roche, James F. Demarest, Fraser Drummond, P. Richard Harrigan, Melissa J. Churchill, Paul R. Gorry*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

35 Citations (Scopus)


Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infected individuals, yet achieving better access to vulnerable populations remains a challenge. The principal obstacle to the CCR5-antagonist, maraviroc, from being more widely used in anti-HIV-1 therapy regimens is that the pre-treatment genotypic œ tropism tests to determine virus susceptibility to maraviroc have been developed primarily for HIV-1 subtype B strains, which account for only 10% of infections worldwide. We therefore developed PhenoSeq, a suite of HIV-1 genotypic tropism assays that are highly sensitive and specific for establishing the tropism of HIV-1 subtypes A, B, C, D and circulating recombinant forms of subtypes AE and AG, which together account for 95% of HIV-1 infections worldwide. The PhenoSeq platform will inform the appropriate use of maraviroc and future CCR5 blocking drugs in regions of the world where non-B HIV-1 predominates, which are burdened the most by the HIV-1 pandemic.

Original languageEnglish
Article number8543
JournalScientific Reports
Publication statusPublished - 2015


Dive into the research topics of 'Reliable genotypic tropism tests for the major HIV-1 subtypes'. Together they form a unique fingerprint.

Cite this